Latest Conference Coverage

Extended-Release Amantadine Shows Reduction in Dyskinesia Severity for Parkinson Disease

Amantadine extended-release capsules, approved for levodopa-related dyskinesia and OFF episodes in Parkinson disease, offer high amantadine concentrations that peak in the time of first morning levodopa dose.

Positive 24-Month Data of Cell Therapy Bemdaneprocel in Parkinson Disease: Amit Rakhit, MD

The chief medical officer and chief development officer at BlueRock Therapeutics provided perspective on newly presented data investigating a cell therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]

Mechanism Behind Ulixacaltamide to Treat Essential Tremor: Marcio Souza

The president and chief executive officer at Praxis Precision Medicine provided clinical insight on the promising build of ulixacaltamide, an investigational, selective agent in development for essential tremor. [WATCH TIME: 3 minutes]

Randomized Controlled ELATE Study to Test OnabotulinumtoxinA in Upper Limb Essential Tremor

ELATE, a multicenter, randomized, double-blind, placebo-controlled trial, aims to address the limitations of current oral therapies by exploring a targeted, localized treatment option.

Nocturnal and Morning Akinesia Still Prevalent After Nighttime Add-On Parkinson Medications

In a post hoc analysis of the COSMOS study, 24-hour LCIG infusion led to a reduction in nocturnal and morning akinesia, though many patients continued to rely on nighttime add-on medications.

Potential of Device-Assisted Therapy for Advanced-Stage Parkinson Disease: David Devos, MD, PhD

The neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]

Study Data Suggests Difficulties With Mediterranean-Ketogenic Dietary Intervention in Parkinson Disease

While participants responded positively to nutritional guidance and the Mediterranean diet, they expressed negative views on the ketogenic diet due to its restrictive nature, social impracticality, and gastrointestinal side effects of MCT oil.

MDS Poster Highlights Long-Term Sustained Efficacy of Adjunctive Continuous Subcutaneous Apomorphine Infusion

Patients reported increased good ON time and improved confidence in daily activities while experiencing a lower treatment burden compared to their previous medication regimens.

A-Synuclein Antibody Lu AF82422 Shows Disease-Modifying Potential in Phase 2 AMULET Trial of MSA

Lu AF84222 was considered well tolerated, with greater treatment effects observed in a subgroup of patients with less impaired multiple system atrophy.

Continued Progress in Path to Prevention Therapeutics Platform Trial of Stage 2B Neuronal Alpha-Synuclein Disease

Path to Prevention is a platform, phase 2 trial that will investigate the safety and efficacy of investigational interventions in patients neuronal α-synuclein disease stage 2B.

Severe Cholinergic Denervation Observed in Parkinson Disease Relative to Progressive Supranuclear Palsy-Parkinsonism

Findings from a new study presented at MDS 2024 suggest that variations in cholinergic denervation patterns may hold promise for differentiating Parkinson disease and progressive supranuclear palsy with parkinsonism.

Parkinson Disease Cognition Improved in Phase 2 Study of TAK-071

Despite showing no differences vs placebo on the primary end point of gait parameters, TAK-071-treated patients demonstrated significant improvements in global cognition score.

Perspectives on Updated McDonald Criteria to Transform MS Diagnosis: Wallace Brownlee, MBChB, PhD, FRACP

The consultant neurologist at Queen's Square MS Center in London gave his clinical viewpoint on the newest revision of the McDonald criteria for diagnosing patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Addressing the Neurologist Shortage Through Career Opportunities and Supporting Early Investigators: Claire Henchcliffe, MD, DPhil, FANA; Ali Ezzati, MD

A pair of neurologists from the University of California, Irvine, detailed some of the training and career focuses of large federal agencies in effort to address the shortage of neurologists. [WATCH TIME: 4 minutes]

A Melting Pot of Strategies and Collaboration at the 2025 MDA Conference: Sharon Hesterlee, PhD

The chief research officer of the Muscular Dystrophy Association talked about what is to be expected at the 2025 MDA Conference, held March 16-19, in Dallas, Texas. [WATCH TIME: 5 minutes]

Using the DAAE Score to Advance Personalized Medicine for Multiple Sclerosis: Tom Fuchs, MD, PhD

The postdoctoral researcher at Amsterdam University Medical Center talked about the DAAE score 2.0 which offers an improved, validated clinical tool to predict the risk of transitioning to secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

NeuroVoices: Wallace Brownlee, MBChB, PhD, FRACP, on Moving Toward a Unified, Biology-Driven Approach in the New Diagnostic Criteria for MS

The consultant neurologist at Queen's Square MS Center in London discussed the shift in the updates to the McDonald criteria for multiple sclerosis presented at ECTRIMS 2024.

Cutting-Edge, Multi-Arm OCTOPUS Trial Continues to Progress Well

Recruitment for the OCTOPUS trial, which explores alpha-lipoic acid and metformin in progressive multiple sclerosis (MS), is progressing well with nearly half of participants in stage 1 already randomized.

Key Challenges and Future Directions of Targeting mTOR for Epileptic Disorders: Ghayda Mirzaa, MD

The principal investigator at Seattle Children’s Research Institute described some of the ongoing questions that remain with developing therapeutics that target mTOR signaling pathway in pediatric epilepsy conditions. [WATCH TIME: 3 minutes]

MSDA Scores Indicate Differing Disease Activity Trajectories With Ublituximab vs Teriflunomide

In the ULTIMATE study subgroup, ublituximab consistently lowered disease activity in MS patients, suggesting the MSDA test may effectively assess therapeutic efficacy.

MAGNIFY-MS Extension Study Confirms Long-term Efficacy of Cladribine Tablets in Relapsing Multiple Sclerosis

A new study presented at ECTRIMS 2024 revealed that 80% of patients with relapsing multiple sclerosis had an estimated no evidence of disease activity rate at both 3 and 4 years when discontinuing cladribine tablets.

Epstein-Barr Virus Immune Response Specific to Multiple Sclerosis Relative to Other Demyelinating Diseases

Results showed that the immune response observed in patients with multiple sclerosis was specifically modified by treatments interfering with Epstein-Barr virus hosts cells or activated lymphocytes.

Sustained Reductions of Brain Atrophy Observed With S1P Modulator Ozanimod

In the original phase 3 studies, treatment with ozanimod resulted in significant reductions in clinical relapses and lesion counts on MRI as well as slowed brain volume loss relative to intramuscular interferon-β-1a.

End-of-Dose Phenomena Observed With Multiple Sclerosis Medication Ofatumumab

Towards the end of ofatumumab dosing, administered monthly via subcutaneous injection, patients noted issues like fatigue, cognitive impairment, and gait difficulties.

Simvastatin Fails to Reduce Disease Progression in Phase 3 MS-STAT2 Trial of Secondary Progressive Multiple Sclerosis

A phase 3 trial revealed that simvastatin, while safe, did not significantly slow disability progression in patients with non-active secondary progressive MS.

Tolebrutinib Shows Positive Results in Slowing Disability Progression for Non-Relapsing Secondary Progressive MS in Phase 3 HERCULES Trial

In a phase 3 study, tolebrutinib demonstrated a statistically significant delay in time to onset of confirmed disability progression in patients living with non-relapsing secondary progressive multiple sclerosis.

Phase 3 MOGwAI Trial to Test Azathioprine as First-Line Treatment for MOGAD

The randomized phase 3 trial will test the hypothesis that the initiation of azathioprine after a first attack of MOGAD could prevent further relapse and disability accrual.

The Promising Results of Tolebrutinib for Secondary Progressive Multiple Sclerosis Treatment: Robert J. Fox, MD

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about a promising therapy that slows the progression of disability in non-relapsing secondary progressive multiple sclerosis. [WATCH TIME: 2 minutes]

Tolebrutinib Slows Disability Worsening in GEMINI Trials of Relapsing MS, Despite Failing to Meet Primary End Point

The positive finding on the secondary end point of 6-month confirmed disability worsening supports the data from the phase 3 HERCULES trial in secondary progressive multiple sclerosis.

Comparative Analysis Insights on Neuromyelitis Optica Spectrum Disorder Treatments: Shamik Bhattacharyya, MD

The associate professor of neurology at Harvard Medical School discussed a study presented at ECTRIMS 2024 that compared the effectiveness and safety profiles of FDA-approved NMOSD therapies with other commonly used treatments. [WATCH TIME: 4 minutes]